951:
reported. In particular, F(ab')2-dependent action of immunoglobulin to inhibit activation of human dendritic cells, induction of autophagy, induction of COX-2-dependent PGE-2 in human dendritic cells leading to expansion of regulatory T cells, inhibition of pathogenic Th17 responses, and induction of human basophil activation and IL-4 induction via anti-IgE autoantibodies. Some believe that immunoglobulin therapy may work via a multi-step model where the injected immunoglobulin first forms a type of
947:, FcgRIIB, and shorten the half-life of auto-reactive antibodies. The ability of immunoglobulin therapy to suppress pathogenic immune responses by this mechanism is dependent on the presence of a sialylated glycan at position CH2-84.4 of IgG. Specifically, de-sialylated preparations of immunoglobulin lose their therapeutic activity and the anti-inflammatory effects of IVIG can be recapitulated by administration of recombinant sialylated IgG1 Fc.
36:
487:(usually involving IgG2 or IgG3), to other disorders in which antibodies are within a normal quantitative range, but lacking in quality – unable to respond to antigens as they normally should – resulting in an increased rate or increased severity of infections. In these situations, immunoglobulin infusions confer passive resistance to infection on their recipients by increasing the quantity/quality of
740:
when compared to intravenous administration (hyaluronidase-assisted subcutaneous administration is associated with a greater frequency of adverse effects than traditional subcutaneous administration but still a lower frequency of adverse effects when compared to intravenous administration). Patients who are receiving immunoglobulin and experience adverse events are sometimes recommended to take
5206:
1116:, various brand names of immunoglobulin products are not necessarily interchangeable, and care must be exercised when changing between them. Brand names of intravenous immunoglobulin formulations include Flebogamma, Gamunex, Privigen, Octagam, and Gammagard, while brand names of subcutaneous formulations include Cutaquig, Cuvitru, HyQvia, Hizentra, Gamunex-C, and Gammaked.
759:(reddening of the skin around the injection site), itching, rash, and hives. Less serious systemic side effects to immunoglobulin infusions include an increased heart rate, hyper or hypotension, an increased body temperature, diarrhea, nausea, abdominal pain, vomiting, arthralgia or myalgia, dizziness, headache, fatigue, fever, and pain.
814:. hemoThere is also a small chance that even given the precautions taken in preparing immunoglobulin preparations, an immunoglobulin infusion may pass a virus to its recipient. Some immunoglobulin solutions also contain isohemagglutinins, which in rare circumstances can cause hemolysis by the isohemagglutinins triggering phagocytosis.
1125:
officially endorsed the idea of not paying for plasma donations for both ethical reasons and reasons of safety, but studies have found that relying on entirely voluntary plasma donation leads to shortages of immunoglobulin and forces member countries to import immunoglobulin from countries that do compensate donors.
950:
Sialylated-Fc-dependent mechanism was not reproduced in other experimental models suggesting that this mechanism is functional under a particular disease or experimental settings. On the other hand, several other mechanisms of action and the actual primary targets of immunoglobulin therapy have been
739:
Although immunoglobulin is frequently used for long periods of time and is generally considered safe, immunoglobulin therapy can have severe adverse effects, both localized and systemic. Subcutaneous administration of immunoglobulin is associated with a lower risk of both systemic and localized risk
1128:
In
Australia, blood donation is voluntary and therefore to cope with increasing demand and to reduce the shortages of locally produced immunoglobulin, several programs have been undertaken including adopting plasma for first time blood donors, better processes for donation, plasma donor centres and
1072:
contain high amounts of an antibody, as a consequence of disease convalescence or of repeated immunization. Hyperimmune plasma is used in veterinary medicine, and hyperimmune plasma derivatives are used to treat snakebite. It has been hypothesized that hyperimmune serum may be an effective therapy
687:
for primary immunodeficiencies, while noting that such usage actually accounts for a minority of usage and acknowledging that immunoglobulin supplementation can be appropriately used for a number of other conditions, including neonatal sepsis (citing a sixfold decrease in mortality), considered in
564:
The
National Advisory Committee on Blood and Blood Products of Canada (NAC) and Canadian Blood Services have also developed their own separate set of guidelines for the appropriate use of immunoglobulin therapy, which strongly support the use of immunoglobulin therapy in primary immunodeficiencies
870:
Intravenous formulations began to be approved in the 1980s, which represented a significant improvement over intramuscular injections, as they allowed for a sufficient amount of immunoglobulin to be injected to reach clinical efficacy, although they still had a fairly high rate of adverse effects
887:
During the late 1980s and early 1990s, it became obvious that for at least a subset of patients the systemic adverse events associated with intravenous therapy were still not easily tolerable, and more doctors began to experiment with subcutaneous immunoglobulin administration, culminating in an
1124:
The United States is one of a handful of countries that allow plasma donors to be paid, meaning that the US supplies much of the plasma-derived medicinal products (including immunoglobulin) used across the world, including more than 50% of the
European Union's supply. The Council of Europe has
549:
The
Australian Red Cross Blood Service developed their own guidelines for the appropriate use of immunoglobulin therapy in 1997. Immunoglobulin is funded under the National Blood Supply and indications are classified as either an established or emerging therapeutic role or conditions for which
861:
before the widespread availability of vaccines. Intramuscular injections were extremely poorly tolerated due to their extreme pain and poor efficacy – rarely could intramuscular injections alone raise plasma immunoglobulin levels enough to make a clinically meaningful difference.
696:(pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection) until further evidence to support its use is found (though noting that it may be useful in PANDAS patients with an autoimmune component), cystic fibrosis, and a number of other conditions.
577:
In the EU human normal immunoglobulin (SCIg) (Hizentra) is used in people whose blood does not contain enough antibodies (proteins that help the body to fight infections and other diseases), also known as immunoglobulins. It is used to treat the following conditions:
900:
In the later 1990s, large-scale trials began in Europe to test the feasibility of subcutaneous immunoglobulin administration, although it was not until 2006 that the first subcutaneous-specific preparation of immunoglobulin was approved by a major regulatory agency
883:
route of administration for immunoglobulin therapy dates back to 1980, but for many years subcutaneous administration was considered to be a secondary choice, only to be considered when peripheral venous access was no longer possible or tolerable.
573:
Brands include HyQvia (human normal immunoglobulin), Privigen (human normal immunoglobulin (IVIg)), Hizentra (human normal immunoglobulin (SCIg)), Kiovig (human normal immunoglobulin), and
Flebogamma DIF (human normal immunoglobulin).
3791:
4361:
1145:, but no such benefit was found in a subsequent phase III clinical trial. In May 2020, the US approved a phase three clinical trial on the efficacy and safety of high-concentration intravenous immune globulin therapy in severe
905:, which was voluntarily discontinued in 2011). A number of other brand names of subcutaneous immunoglobulin have since been approved, although some small-scale studies have indicated that a particular cohort of patients with
4525:
1332:
4427:"An EU-wide overview of the market of blood, blood components and plasma derivatives focusing on their availability for patients Creative Ceutical Report, revised by the Commission to include stakeholders' comments"
589:
low levels of antibodies in the blood in people before or after allogeneic haematopoietic stem cell transplantation (a procedure where the patient's bone marrow is cleared of cells and replaced by stem cells from a
628:
hypogammaglobulinaemia (low levels of antibodies) and recurrent bacterial infections in plateau-phase-multiple-myeloma (another cancer of a type of white blood cell) patients who failed to respond to pneumococcal
624:
hypogammaglobulinaemia (low levels of antibodies) and recurrent bacterial infections in patients with chronic lymphocytic leukaemia (a cancer of a type of white blood cell), in whom prophylactic antibiotics have
632:
hypogammaglobulinaemia (low levels of antibodies) in patients after allogenic haematopoietic-stem-cell transplantation (HSCT) (when the patient receives stem cells from a matched donor to help restore the bone
482:
Immunoglobulin therapy is used in a variety of conditions, many of which involve decreased or abolished antibody production capabilities, which range from a complete absence of multiple types of antibodies, to
2833:
Daw Z, Padmore R, Neurath D, Cober N, Tokessy M, Desjardins D, et al. (August 2008). "Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis".
896:
trial resulted in a severe systemic adverse reaction, and most subcutaneous injections were able to be administered in non-hospital settings, allowing for considerably more freedom for the people involved.
585:
low levels of antibodies in the blood in people with chronic lymphocytic leukaemia (a cancer of a type of white blood cell) or myeloma (a cancer of another type of white blood cell) and who have frequent
4261:
1364:
1240:
4045:"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis"
962:
Other proposed mechanisms include the possibility that donor antibodies may bind directly with the abnormal host antibodies, stimulating their removal; the possibility that IgG stimulates the host's
3957:
Bayry J, Thirion M, Misra N, Thorenoor N, Delignat S, Lacroix-Desmazes S, et al. (October 2003). "Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases".
836:(like MMR) for up to a year, can result in falsely elevated blood glucose levels, and can interfere with many of the IgG-based assays often used to diagnose a patient with a particular infection.
663:
recommends the routine use of immunoglobulin for a variety of conditions including primary immunodeficiencies and a number of other conditions, but recommends against the use of immunoglobulin in
593:
chronic inflammatory demyelinating polyneuropathy (CIDP). In this rare disease, the immune system (the body's defence system) works abnormally and destroys the protective covering over the nerves.
541:. The high demand which coupled with the difficulty of producing immunoglobulin in large quantities has resulted in increasing global shortages, usage limitations and rationing of immunoglobulin.
3204:
Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. (October 1998). "Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin".
892:
clinical trial in Sweden of 3000 subcutaneous injections administered to 25 adults (most of whom had previously experienced systemic adverse effects with IMIg or IVIg), where no infusion in the
3708:
Maddur MS, Vani J, Hegde P, Lacroix-Desmazes S, Kaveri SV, Bayry J (March 2011). "Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin".
3752:
3583:
Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, et al. (January 2003). "Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin".
4290:
2278:
4573:
4350:
1722:"Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology"
1001:
in T cell-microglia co-culture. The results add to the understanding of how immunoglobulin may affect inflammation of the central nervous system in autoimmune inflammatory diseases.
249:
748:
before their infusions to reduce the rate of adverse effects. Additional premedication may be required in some instances (especially when first getting accustomed to a new dosage),
1270:
4547:
1300:
2912:
Sugita K, Eguchi M (January 2005). "Suppressive effect of intravenous immunoglobulin on peripheral blood neutrophil count in patients with idiopathic thrombocytopenic purpura".
3460:
688:
cases of HIV (including pediatric HIV), considered as a second line treatment in relapsing-remitting multiple sclerosis, but recommending against its use in such conditions as
2028:
Anderson D, Ali K, Blanchette V, Brouwers M, Couban S, Radmoor P, et al. (April 2007). "Guidelines on the use of intravenous immune globulin for hematologic conditions".
1057:. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious
4398:
4100:
2811:
1322:
1210:
446:
Human immunoglobulin therapy first occurred in the 1930s and a formulation for injection into a vein was approved for medical use in the United States in 1981. It is on the
3914:
Siragam V, Crow AR, Brinc D, Song S, Freedman J, Lazarus AH (June 2006). "Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells".
4499:
2675:
2615:
2555:
2495:
2435:
1496:
1463:
1430:
1397:
2877:
Lassiter HA, Bibb KW, Bertolone SJ, Patel CC, Stroncek DF (February 1993). "Neonatal immune neutropenia following the administration of intravenous immune globulin".
1104:
1,200.00 depending on the type and amount. In the United States, antivenoms may cost thousands of dollars per dose because of markups that occur after manufacturing.
857:
formulations (IVIg) began to be introduced in the 1980s. During the mid and late 1950s, one-time IMIg injections were a common public health response to outbreaks of
5134:
5114:
4705:
2778:
2405:
5109:
2735:
4245:
966:, leading to enhanced removal of all antibodies, including the harmful ones; and the ability of immunoglobulin to block the antibody receptors on immune cells (
5246:
5124:
1354:
1232:
204:
4433:
4327:
2465:
2645:
2585:
2375:
2345:
2525:
2315:
680:
3152:
4521:
373:
3324:
1149:. Efficacy of heterologous immunoglobulin derivatives has been demonstrated in clinical trials of antivenoms for scorpion sting and for snakebite.
2271:
1812:"Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology"
4283:
4565:
2225:
Text was copied from this source which is copyright
European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
2212:
2110:
Text was copied from this source which is copyright
European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
4864:
4698:
3669:"Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells"
909:(CVID) may develop intolerable side effects with subcutaneous immunoglobulin (SCIg) that they do not with intravenous immunoglobulin (IVIg).
108:
902:
4551:
3536:"Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils"
1262:
3177:
Lee Martin N, Butani Lavjay (2005). "Intravenous
Immunoglobulin (IVIG) in Rheumatologic Diseases: A Review of its Mechanism of Action".
2131:
2097:
1647:
1292:
2164:
1532:
613:
replacement therapy in myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections.
3429:
829:/cell death due to antineutrophil antibodies with or without neutrophil migration into a storage pool outside the blood circulation.
392:, and certain other infections when a more specific immunoglobulin is not available. Depending on the formulation it can be given by
4130:
4691:
4387:
4092:
491:
they possess. Immunoglobulin therapy is also used for a number of other conditions, including in many autoimmune disorders such as
2803:
2705:
1573:
1202:
4490:
565:
and some complications of HIV, while remaining silent on the issues of sepsis, multiple sclerosis, and chronic fatigue syndrome.
2667:
2607:
2547:
2487:
2427:
1488:
1455:
1422:
1389:
5119:
5073:
959:, which then mediate anti-inflammatory effects helping to reduce the severity of the autoimmune disease or inflammatory state.
644:
primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count;
811:
447:
2246:
3620:"Intravenous immunoglobulin mediates anti-inflammatory effects in peripheral blood mononuclear cells by inducing autophagy"
2989:
145:
2769:
2397:
4466:
2006:
935:
Perhaps a more popular theory is that the immunosuppressive effects of immunoglobulin therapy are mediated through IgG's
822:
3818:"Anti-IgE IgG autoantibodies isolated from therapeutic normal IgG intravenous immunoglobulin induce basophil activation"
1180:
495:
in an attempt to decrease the severity of symptoms. Immunoglobulin therapy is also used in some treatment protocols for
556:
Human normal immunoglobulin (human immunoglobulin G) (Cutaquig) was approved for medical use in
Australia in May 2021.
2727:
4857:
1946:
1641:
1614:
3040:"Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease"
1916:
832:
Immunoglobulin therapy interferes with the ability of the body to produce a normal immune response to an attenuated
762:
Serious side effects of immunoglobulin infusions in infants, children, and adults include chest discomfort or pain,
4932:
4636:
Williams DJ, Habib AG, Warrell DA (August 2018). "Clinical studies of the effectiveness and safety of antivenoms".
1174:
906:
5236:
4426:
467:
369:
234:
126:
4315:
4152:
Dias da Silva W, De
Andrade SA, Megale ÂA, De Souza DA, Sant'Anna OA, Magnoli FC, et al. (September 2022).
2457:
989:
A report stated that immunoglobulin application to activated T cells leads to their decreased ability to engage
4983:
2637:
2577:
2367:
2337:
936:
56:
2517:
2303:
597:
It is indicated for replacement therapy in adults and children in primary immunodeficiency syndromes such as:
582:
primary immunodeficiency syndromes (PID, when people are born with an inability to produce enough antibodies);
538:
389:
5241:
5178:
4901:
4000:
Janke AD, Yong VW (April 2006). "Impact of IVIg on the interaction between activated T cells and microglia".
3304:
617:
Flebogamma DIF is indicated for the replacement therapy in adults, children and adolescents (0–18 years) in:
3141:
4978:
4950:
4850:
4357:
4321:
2309:
1976:
916:(FDA) approved the first preparation of immunoglobulin that was designed exclusively for subcutaneous use.
913:
500:
336:
4970:
3487:"Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin"
5231:
5162:
4751:
994:
512:
51:
4595:
Boyer LV, Theodorou AA, Berg RA, Mallie J, Chávez-Méndez A, García-Ubbelohde W, et al. (May 2009).
912:
Although intravenous was the preferred route for immunoglobulin therapy for many years, in 2006, the US
5196:
5068:
5027:
4960:
4733:
2804:"Comparing Two Treatments for IVIG-Resistant Kawasaki Disease - Evidence Update for Clinicians | PCORI"
553:
Subcutaneous immunoglobulin access programs have been developed to facilitate hospital based programs.
455:
4043:
Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. (January 2015).
974:. Indeed, it is becoming more clear that immunoglobulin can bind to a number of membrane receptors on
5183:
5048:
3430:"Circulating Normal IgG as Stimulator of Regulatory T Cells: Lessons from Intravenous Immunoglobulin"
3089:
Misbah S, Sturzenegger MH, Borte M, Shapiro RS, Wasserman RL, Berger M, et al. (December 2009).
2206:
2158:
2125:
2091:
1909:"Criteria for the Clinical Use of Intravenous Immunoglobulin in Australia | National Blood Authority"
1689:
1661:
1526:
3618:
Das M, Karnam A, Stephen-Victor E, Gilardin L, Bhatt B, Kumar Sharma V, et al. (January 2020).
3753:"Intravenous immunoglobulin induces IL-4 in human basophils by signaling through surface-bound IgE"
2201:
689:
424:
365:
2953:
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology
928:
is likely multifactorial. For example, it has been reported that immunoglobulin therapy can block
825:, resolving spontaneously and without complications within 48 h. Possible pathomechanisms include
667:(unless a specific toxin has been identified), multiple sclerosis, neonatal sepsis, and pediatric
5104:
5083:
4741:
3751:
Galeotti C, Stephen-Victor E, Karnam A, Das M, Gilardin L, Maddur MS, et al. (August 2019).
3485:
Othy S, Topçu S, Saha C, Kothapalli P, Lacroix-Desmazes S, Käsermann F, et al. (July 2014).
1810:
Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, et al. (September 2003).
940:
850:
756:
660:
537:
infection and is also considered the standard of treatment for some autoimmune disorders such as
504:
451:
193:
182:
90:
4205:"Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections"
5226:
4831:
4756:
4746:
4566:"FDA Approves Octapharma USA Investigational New Drug Application for Severe COVID-19 Patients"
4284:"Eight Guiding Principles for Effective Use of IVIG for Patients with Primary Immunodeficiency"
3256:"Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: a critical review"
1142:
1042:
955:
in the patient. Once these immune complexes are formed, they can interact with Fc receptors on
880:
471:
463:
401:
197:
1631:
4724:
2120:
2086:
763:
516:
459:
393:
3254:
Maverakis E, Kim K, Shimoda M, Gershwin ME, Patel F, Wilken R, et al. (February 2015).
993:. As a result of immunoglobulin treatment of T cells, the findings showed reduced levels of
5019:
4645:
3213:
2153:
1720:
Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. (April 2006).
1521:
364:(normal human immunoglobulin) to treat several health conditions. These conditions include
345:
17:
636:
congenital acquired immune deficiency syndrome (AIDS) with recurrent bacterial infections.
309:
8:
5077:
4905:
4873:
4788:
4122:
3534:
Campbell IK, Miescher S, Branch DR, Mott PJ, Lazarus AH, Han D, et al. (June 2014).
854:
799:
300:
189:
45:
4683:
4649:
4522:"Experimental Alzheimer's drug Gammagard may stall memory decline, small study suggests"
3667:
Trinath J, Hegde P, Sharma M, Maddur MS, Rabin M, Vallat JM, et al. (August 2013).
3217:
1761:
van Doorn PA, Kuitwaard K, Walgaard C, van Koningsveld R, Ruts L, Jacobs BC (May 2010).
4669:
4180:
4153:
4069:
4044:
4025:
3982:
3939:
3842:
3817:
3783:
3733:
3644:
3619:
3560:
3535:
3516:
3364:
3339:
3280:
3255:
3117:
3066:
3039:
2925:
2859:
2697:
1890:
1841:
1787:
1762:
1569:
1355:"Drug and medical device highlights 2018: Helping you maintain and improve your health"
833:
817:
IVIG has long been known to induce a decrease in peripheral blood neutrophil count, or
807:
795:
647:
Guillain–Barré syndrome, which causes multiple inflammations of the nerves in the body;
520:
408:
156:
118:
78:
3891:
3866:
5139:
4955:
4661:
4618:
4253:
4226:
4185:
4074:
4017:
3974:
3931:
3896:
3847:
3775:
3725:
3690:
3649:
3600:
3565:
3508:
3452:
3410:
3369:
3285:
3229:
3122:
3107:
3090:
3071:
2970:
2929:
2894:
2890:
2851:
2847:
2488:"Hyqvia (immune globulin 10 percent – human with recombinant human hyaluronidase kit"
2045:
1894:
1882:
1833:
1792:
1743:
1637:
1610:
1113:
963:
601:
congenital agammaglobulinaemia and hypogammaglobulinaemia (low levels of antibodies);
524:
496:
273:
261:
4673:
4029:
3943:
3787:
3520:
3142:"Re: A Message from CSL Behring to Current Vivaglobin Patients in the United States"
1845:
4924:
4653:
4608:
4216:
4175:
4165:
4064:
4056:
4009:
3986:
3966:
3923:
3886:
3878:
3837:
3829:
3767:
3737:
3717:
3680:
3639:
3631:
3592:
3555:
3547:
3498:
3444:
3400:
3359:
3351:
3316:
3275:
3267:
3221:
3186:
3112:
3102:
3061:
3051:
2960:
2921:
2886:
2863:
2843:
2037:
1872:
1823:
1782:
1774:
1733:
1697:
1669:
1046:
779:
650:
Kawasaki disease, which causes multiple inflammation of several organs in the body.
508:
488:
377:
4657:
4203:
Kudoyarova-Zubavichene NM, Sergeyev NN, Chepurnov AA, Netesov SV (February 1999).
3816:
Galeotti C, Karnam A, Dimitrov JD, Chevailler A, Kaveri SV, Bayry J (April 2020).
1233:"Prescription medicines: registration of new chemical entities in Australia, 2014"
1203:"Prescription medicines: registration of new chemical entities in Australia, 2016"
1169:
640:
and for the immunomodulation in adults, children and adolescents (0–18 years) in:
530:
Immunoglobulin therapy is especially useful in some acute infection cases such as
5210:
4942:
4913:
4909:
3685:
3668:
3225:
2990:"Laboratory Serologic Problems Associated with Administration of Intravenous IgG"
2235:
1054:
956:
745:
492:
412:
217:
3721:
3001:
718:
Hyqvia (immune globulin 10 percent – human with recombinant human hyaluronidase)
5129:
5043:
5004:
4597:"Antivenom for critically ill children with neurotoxicity from scorpion stings"
3771:
3596:
3305:"Antiinflammatory Activity of IVIG Mediated through the Inhibitory FC Receptor"
3271:
3190:
2041:
1738:
1721:
1138:
1010:
998:
952:
684:
484:
428:
4458:
4202:
3970:
3833:
3635:
1998:
1778:
5220:
5099:
4888:
4816:
4257:
3551:
3448:
3320:
1694:
World Health Organization model list of essential medicines: 22nd list (2021)
1359:
1327:
1065:
741:
4246:"The crazy reason it costs $ 14,000 to treat a snakebite with $ 14 medicine"
4060:
4013:
3405:
3388:
407:
Common side effects include pain at the site of injection, muscle pain, and
5157:
4796:
4715:
4665:
4622:
4189:
4170:
4078:
4021:
3978:
3935:
3900:
3851:
3779:
3729:
3694:
3653:
3604:
3569:
3512:
3456:
3414:
3373:
3289:
3126:
3075:
3000:. The University of Texas M. D. Anderson Cancer Center: 1–7. Archived from
2974:
2933:
2855:
2049:
1886:
1837:
1796:
1747:
1666:
World Health Organization model list of essential medicines: 21st list 2019
1069:
1026:
971:
970:), leading to decreased damage by these cells, or regulation of macrophage
929:
925:
771:
436:
212:
4613:
4596:
4230:
3503:
3486:
3389:"IVIG-mediated effector functions in autoimmune and inflammatory diseases"
3233:
2898:
2272:"Eight guiding principals for safe, effective and appropriate use of IVIG"
1938:
755:
Local side effects of immunoglobulin infusions most frequently include an
4896:
4826:
4821:
4801:
4356:(Report). Review Office Signatory Authority Tejashri Purohit-Sheth. U.S.
3355:
1908:
1828:
1811:
1760:
1633:
Primary Immunodeficiency Disorders: A Historic and Scientific Perspective
1074:
1058:
1030:
986:
that are pertinent to autoreactivity and induction of tolerance to self.
944:
924:
The precise mechanism by which immunoglobulin therapy suppresses harmful
818:
803:
791:
767:
527:) some acute infections and some complications of organ transplantation.
420:
416:
397:
4042:
2965:
2948:
2792:(Subscription may be required or content may be available in libraries.)
1702:
1674:
1029:. Some agents against which hyperimmune globulins are available include
5009:
4811:
3056:
967:
783:
749:
361:
320:
4842:
1877:
1860:
103:
normal human immunoglobulin (HNIG), human normal immunoglobulin (HNIG)
4806:
4774:
4766:
4151:
3882:
990:
983:
826:
787:
775:
621:
primary immunodeficiency syndromes with impaired antibody production;
450:. Each formulation of the product is somewhat different. A number of
432:
112:
3582:
4221:
4204:
3927:
3340:"The antiinflammatory activity of IgG: the intravenous IgG paradox"
1609:(69 ed.). British Medical Association. 2015. pp. 867–71.
1146:
1129:
encouraging current blood donors to consider plasma only donation.
1018:
668:
531:
381:
140:
871:(though the addition of stabilizing agents reduced this further).
2947:
Stoevesandt J, Heitmann J, Goebeler M, Benoit S (December 2020).
2946:
1050:
1038:
1022:
979:
975:
610:
immunoglobulin-G-subclass deficiencies with recurrent infections;
440:
385:
3815:
1968:
3750:
3707:
3617:
1034:
693:
664:
3088:
2668:"Xembify – immune globulin subcutaneous, human-klhw solution"
2027:
858:
3253:
3203:
3176:
2548:"Octagam immune globulin (human)- immune globulin solution"
3956:
3533:
2876:
1809:
1141:
in humans suggested protection against the progression of
4713:
1763:"IVIG treatment and prognosis in Guillain-Barré syndrome"
1688:
1660:
1423:"Bivigam (immune globulin intravenous – human 10% liquid"
1095:
1091:
849:
After immunoglobulin therapy's discovery in 1952, weekly
550:
immunoglobulin use is in exceptional circumstances only.
534:
4594:
4289:. American Association of Allergists and Immunologists.
3666:
3091:"Subcutaneous immunoglobulin: opportunities and outlook"
3037:
2277:. American Association of Allergists and Immunologists.
1719:
1678:. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
1049:
to the patient against an agent. This is in contrast to
709:
Bivigam (immune globulin intravenous – human 10% liquid)
3484:
2608:"Panzyga (immune globulin intravenous – human solution"
1045:, etc. Administration of hyperimmune globulin provides
448:
World Health Organization's List of Essential Medicines
3038:
Skoda-Smith S, Torgerson TR, Ochs HD (February 2010).
2832:
1450:
1448:
427:. Use is not recommended in people with some types of
5194:
4154:"Antibodies as Snakebite Antivenoms: Past and Future"
2879:
The American Journal of Pediatric Hematology/Oncology
1572:. The American Society of Health-System Pharmacists.
943:, IVIG can increase the expression of the inhibitory
4635:
3913:
1991:
727:
Xembify (immune globulin subcutaneous, human – klhw)
3386:
1483:
1481:
1445:
1417:
1415:
1384:
1382:
724:
Panzyga (immune globulin intravenous, human – ifas)
706:
Asceniv (immune globulin intravenous, human – slra)
681:
American Academy of Allergy, Asthma, and Immunology
43:It has been suggested that this article should be
4489:
2768:
2420:
3427:
3337:
2660:
2600:
2540:
2196:
2194:
2192:
2190:
2188:
2186:
2184:
2182:
2081:
2079:
730:Yimmugo (immune globulin intravenous, human-dira)
374:chronic inflammatory demyelinating polyneuropathy
5218:
4548:"Another Alzheimer's Drug Fails Phase III Trial"
3387:Galeotti C, Kaveri SV, Bayry J (December 2017).
3249:
3247:
3245:
3243:
2480:
2077:
2075:
2073:
2071:
2069:
2067:
2065:
2063:
2061:
2059:
1478:
1412:
1379:
3428:Maddur MS, Kaveri SV, Bayry J (November 2017).
1164:
1162:
703:Alyglo (immune globulin intravenous human-stwk)
308:
4487:
4351:Summary Basis for Regulatory Action – Hizentra
3867:"Immune complexes as therapy for autoimmunity"
3760:The Journal of Allergy and Clinical Immunology
3710:The Journal of Allergy and Clinical Immunology
2179:
1969:"Access to Subcutaneous Immunoglobulin (SCIg)"
1726:The Journal of Allergy and Clinical Immunology
1516:
1514:
1456:"Gamunex-C (immune globulin – human injection"
454:formulations are also available including for
5247:World Health Organization essential medicines
4858:
4699:
4491:"Small Trial Hints Drug Can Slow Alzheimer's"
3240:
2113:
2056:
1939:"Access to Intravenous Immunoglobulin (IVIg)"
853:of immunoglobulin (IMIg) were the norm until
715:Hizentra (immune globulin subcutaneous human)
2911:
2236:"Clinical Guidelines for Immunoglobulin Use"
1159:
721:Octagam (immune globulin intravenous, human)
712:Gamunex-C, (immune globulin injection human)
144:
4276:
2146:
1715:
1713:
1629:
1564:
1562:
1560:
1558:
1556:
1554:
1552:
1550:
1511:
1017:, except that the donor has high titers of
839:
431:. Use appears to be relatively safe during
287:In general: ℞ (Prescription only)
4865:
4851:
4706:
4692:
2428:"Hizentra – human immunoglobulin g liquid"
2296:
503:(HIV), some autoimmune disorders (such as
435:. Human immunoglobulin is made from human
4612:
4432:. Creative Ceutical & EU commission.
4220:
4179:
4169:
4068:
3999:
3890:
3841:
3684:
3643:
3559:
3502:
3404:
3363:
3338:Nimmerjahn F, Ravetch JV (January 2007).
3279:
3116:
3106:
3065:
3055:
3044:Therapeutics and Clinical Risk Management
2987:
2964:
1876:
1827:
1786:
1737:
1701:
1673:
1390:"Asceniv – human immunoglobulin g liquid"
344:
4243:
3133:
2914:Journal of Pediatric Hematology/Oncology
1852:
1710:
1607:British national formulary : BNF 69
1601:
1599:
1597:
1595:
1593:
1591:
1547:
844:
4872:
4481:
4388:"SCIG: New Therapeutic Uses Beyond PI?"
3302:
3033:
3031:
3029:
3027:
3025:
3023:
3021:
3019:
2763:
2761:
2759:
2757:
2755:
2753:
1858:
1682:
1654:
1489:"Alyglo- human immunoglobulin g liquid"
1263:"Regulatory Decision Summary - Xembify"
1004:
874:
95:Flebogamma, Gammagard, Hizentra, others
14:
5219:
5074:Peripherally inserted central catheter
4421:
4419:
4379:
4348:
3864:
2994:Current Issues in Transfusion Medicine
2021:
2003:Therapeutic Goods Administration (TGA)
1237:Therapeutic Goods Administration (TGA)
1207:Therapeutic Goods Administration (TGA)
1090:In the United Kingdom a dose cost the
1080:
1061:, thus usage is taken very seriously.
919:
865:
439:. It contains antibodies against many
279:
4846:
4687:
4469:from the original on 4 September 2019
4439:from the original on 22 December 2015
3871:The Journal of Clinical Investigation
3158:from the original on 22 December 2015
2558:from the original on 26 February 2024
2318:from the original on 22 December 2023
2264:
2009:from the original on 6 September 2021
1696:. Geneva: World Health Organization.
1668:. Geneva: World Health Organization.
1588:
1009:Hyperimmune globulins are a class of
812:transfusion related acute lung injury
267:
135:
117:
4404:from the original on 27 October 2015
3466:from the original on 1 February 2022
3344:The Journal of Experimental Medicine
3095:Clinical and Experimental Immunology
3016:
2981:
2781:from the original on 8 December 2015
2750:
1803:
1650:from the original on 9 January 2017.
1335:from the original on 19 January 2022
1293:"Summary Basis of Decision - HyQvia"
411:. Other severe side effects include
216:
29:
4601:The New England Journal of Medicine
4416:
3822:Cellular & Molecular Immunology
2228:
1865:American Journal of Transplantation
1754:
1636:. Academic Press. pp. 283–84.
1576:from the original on 9 January 2017
823:Idiopathic Thrombocytopenic Purpura
24:
4385:
4367:from the original on 20 March 2018
4209:The Journal of Infectious Diseases
4133:from the original on 27 March 2023
4049:The Journal of Infectious Diseases
3327:from the original on 11 June 2008.
3139:
2926:10.1097/01.mph.0000149239.68396.72
2648:from the original on 17 April 2024
2498:from the original on 5 August 2020
2408:from the original on 5 August 2024
2378:from the original on 5 August 2024
2100:from the original on 1 August 2020
1367:from the original on 17 April 2024
1303:from the original on 5 August 2024
1243:from the original on 10 April 2023
1213:from the original on 10 April 2023
1137:Experimental results from a small
821:in neonates, and in patients with
25:
5258:
4714:Immune sera and immunoglobulins (
4576:from the original on 21 June 2020
4528:from the original on 19 July 2012
4502:from the original on 19 July 2012
4330:from the original on 1 April 2020
4296:from the original on 5 March 2016
3797:from the original on 7 March 2020
2814:from the original on 30 June 2024
2738:from the original on 19 June 2024
2732:U.S. Food and Drug Administration
2708:from the original on 10 June 2024
2702:U.S. Food and Drug Administration
2642:U.S. Food and Drug Administration
2582:U.S. Food and Drug Administration
2522:U.S. Food and Drug Administration
2468:from the original on 1 April 2020
2462:U.S. Food and Drug Administration
2402:U.S. Food and Drug Administration
2372:U.S. Food and Drug Administration
2348:from the original on 13 June 2024
2342:U.S. Food and Drug Administration
2284:from the original on 5 March 2016
2215:from the original on 15 July 2020
2167:from the original on 17 July 2020
2134:from the original on 15 July 2020
1979:from the original on 1 March 2020
1949:from the original on 2 April 2020
1919:from the original on 1 March 2020
1535:from the original on 15 July 2020
1499:from the original on 3 March 2024
1183:from the original on 14 July 2022
1013:prepared in a similar way as for
654:
607:severe combined immunodeficiency;
604:common variable immunodeficiency;
568:
243:
167:
5204:
4264:from the original on 2 July 2023
4123:"What is Hyperimmunized Plasma?"
3108:10.1111/j.1365-2249.2009.04027.x
2891:10.1097/00043426-199302000-00019
2848:10.1111/j.1537-2995.2008.01721.x
2678:from the original on 9 June 2021
2618:from the original on 9 June 2021
2588:from the original on 31 May 2024
2528:from the original on 19 May 2024
2438:from the original on 9 June 2021
2252:from the original on 29 May 2015
1466:from the original on 9 June 2021
1433:from the original on 9 June 2021
1400:from the original on 9 June 2021
1273:from the original on 7 June 2022
1175:Therapeutic Goods Administration
1119:
907:common variable immunodeficiency
674:
404:. The effects last a few weeks.
34:
4629:
4588:
4558:
4540:
4514:
4488:Andrew Pollack (17 July 2012).
4451:
4342:
4308:
4244:Ingraham C (25 November 2021).
4237:
4196:
4145:
4115:
4103:from the original on 7 May 2023
4085:
4036:
3993:
3950:
3907:
3858:
3809:
3744:
3701:
3660:
3611:
3576:
3527:
3478:
3421:
3380:
3331:
3296:
3197:
3170:
3082:
2940:
2905:
2870:
2826:
2796:
2720:
2690:
2630:
2570:
2510:
2450:
2390:
2360:
2330:
1961:
1931:
1901:
1623:
1021:against a specific organism or
734:
511:), some neurological diseases (
477:
370:immune thrombocytopenic purpura
4397:(February–March 2015): 28–32.
3491:European Journal of Immunology
1767:Journal of Clinical Immunology
1347:
1315:
1285:
1255:
1225:
1195:
1107:
1073:for persons infected with the
256:
13:
1:
5179:Needle and syringe programmes
4658:10.1016/j.toxicon.2018.05.001
1152:
939:. By binding to receptors on
4358:Food and Drug Administration
4322:Food and Drug Administration
3686:10.1182/blood-2012-11-468264
3226:10.1126/science.282.5388.490
3179:Current Rheumatology Reviews
2310:Food and Drug Administration
2030:Transfusion Medicine Reviews
1085:
914:Food and Drug Administration
544:
501:human immunodeficiency virus
497:secondary immunodeficiencies
7:
4752:Hepatitis B immune globulin
4349:Pierce LR (14 March 2018).
3722:10.1016/j.jaci.2010.12.1102
1630:Etzioni A, Ochs HD (2014).
1132:
1015:normal human immunoglobulin
995:tumor necrosis factor-alpha
879:The first description of a
513:multifocal motor neuropathy
360:is the use of a mixture of
52:normal human immunoglobulin
10:
5263:
5069:Peripheral venous catheter
4524:. CBS News. 17 July 2012.
3772:10.1016/j.jaci.2018.10.064
3597:10.1182/blood-2002-05-1447
3272:10.1016/j.jaut.2014.12.002
3191:10.2174/157339705774612355
2988:Lichtiger B (April 1994).
2042:10.1016/j.tmrv.2007.01.001
1859:Pondrom S (October 2014).
1739:10.1016/j.jaci.2006.01.015
1706:. WHO/MHP/HPS/EML/2021.02.
472:Rh positive blood exposure
49:into a new article titled
5184:Supervised injection site
5171:
5150:
5092:
5061:
5036:
5018:
4992:
4969:
4941:
4923:
4887:
4880:
4787:
4765:
4732:
4723:
3971:10.1007/s10072-003-0081-7
3865:Clynes R (January 2005).
3834:10.1038/s41423-019-0334-x
3636:10.1038/s41419-020-2249-y
3149:Primary Immune Foundation
2949:"[Not Available]"
2207:European Medicines Agency
2159:European Medicines Agency
2126:European Medicines Agency
2092:European Medicines Agency
1779:10.1007/s10875-010-9407-4
1690:World Health Organization
1662:World Health Organization
1527:European Medicines Agency
752:or another oral steroid.
559:
485:IgG subclass deficiencies
335:
319:
299:
294:
233:
228:
203:
181:
155:
125:
107:
99:
89:
84:
3624:Cell Death & Disease
3552:10.4049/jimmunol.1301611
3449:10.1016/j.it.2017.08.008
3393:International Immunology
3321:10.1542/peds.110.S2.467a
1973:National Blood Authority
1943:National Blood Authority
941:antigen presenting cells
851:intramuscular injections
840:Routes of administration
690:chronic fatigue syndrome
425:red blood cell breakdown
366:primary immunodeficiency
5135:Thermodilution catheter
5084:Central venous catheter
4742:Anthrax immune globulin
4014:10.1179/016164106X98143
3303:Gern JE (August 2002).
3260:Journal of Autoimmunity
2243:National Health Service
757:injection site reaction
661:National Health Service
539:Guillain–Barré syndrome
505:immune thrombocytopenia
452:specific immunoglobulin
390:Guillain–Barré syndrome
5237:Therapeutic antibodies
5000:Immunoglobulin therapy
4832:Tixagevimab/cilgavimab
4757:Zoster-immune globulin
4747:Rho(D) immune globulin
4215:(Suppl 1): S218–S223.
4171:10.3390/toxins14090606
3965:(Suppl 4): S217–S221.
1732:(4 Suppl): S525–S553.
1323:"Immune system health"
932:-mediated cell death.
358:Immunoglobulin therapy
79:Immunoglobulin therapy
4789:Monoclonal antibodies
4725:Polyclonal antibodies
4614:10.1056/NEJMoa0808455
4061:10.1093/infdis/jiu396
4002:Neurological Research
3959:Neurological Sciences
3540:Journal of Immunology
3504:10.1002/eji.201444440
3406:10.1093/intimm/dxx039
845:1950s – intramuscular
764:myocardial infarction
659:The United Kingdom's
517:stiff person syndrome
394:injection into muscle
5242:Transfusion medicine
5125:Implantable catheter
5020:Parenteral nutrition
4570:www.businesswire.com
4459:"transfusion.com.au"
3437:Trends in Immunology
3356:10.1084/jem.20061788
2644:. 11 February 2021.
2314:. 15 December 2023.
2036:(2 Suppl 1): S9-56.
1829:10.1212/WNL.61.6.736
1495:. 15 December 2023.
1005:Hyperimmune globulin
875:1990s – subcutaneous
683:supports the use of
5078:Seldinger technique
4906:Fresh frozen plasma
4889:Blood-based product
4874:Intravenous therapy
4650:2018Txcn..150....1W
3218:1998Sci...282..490V
2966:10.1111/ddg.14310_g
2554:. 26 January 2024.
2524:. 12 January 2024.
1363:. 14 October 2020.
1299:. 23 October 2014.
1269:. 23 October 2014.
1143:Alzheimer's disease
1081:Society and culture
920:Mechanism of action
866:1980s – intravenous
800:acute kidney injury
468:varicella infection
380:, certain cases of
252:(Prescription only)
81:
5232:Medical treatments
4984:Sodium bicarbonate
4881:Infused substances
4463:transfusion.com.au
3716:(3): 823–30.e1–7.
3101:(Suppl 1): 51–59.
3057:10.2147/tcrm.s4353
2584:. 10 August 2022.
1863:. The AJT Report.
1861:"The IVIg dilemma"
1047:"passive" immunity
834:live-virus vaccine
808:pulmonary embolism
796:aseptic meningitis
521:multiple sclerosis
409:allergic reactions
77:
5192:
5191:
5140:Dialysis catheter
5057:
5056:
4840:
4839:
4783:
4782:
4607:(20): 2090–2098.
4326:. 15 March 2018.
3766:(2): 524–535.e8.
3546:(11): 5031–5038.
3212:(5388): 490–493.
2959:(12): 1394–1404.
2770:"Immune Globulin"
2464:. 21 April 2022.
1878:10.1111/ajt.12995
1871:(10): 2195–2196.
1570:"Immune Globulin"
1055:"active" immunity
964:complement system
525:myasthenia gravis
355:
354:
283:
271:
259:
247:
171:
138:
73:
72:
27:Medical treatment
16:(Redirected from
5254:
5209:
5208:
5207:
5200:
4979:Ringer's lactate
4951:Ringer's lactate
4933:Hemoglobin-based
4925:Blood substitute
4885:
4884:
4867:
4860:
4853:
4844:
4843:
4730:
4729:
4708:
4701:
4694:
4685:
4684:
4678:
4677:
4633:
4627:
4626:
4616:
4592:
4586:
4585:
4583:
4581:
4562:
4556:
4555:
4550:. Archived from
4544:
4538:
4537:
4535:
4533:
4518:
4512:
4511:
4509:
4507:
4493:
4485:
4479:
4478:
4476:
4474:
4455:
4449:
4448:
4446:
4444:
4438:
4431:
4423:
4414:
4413:
4411:
4409:
4403:
4392:
4383:
4377:
4376:
4374:
4372:
4366:
4355:
4346:
4340:
4339:
4337:
4335:
4312:
4306:
4305:
4303:
4301:
4295:
4288:
4280:
4274:
4273:
4271:
4269:
4241:
4235:
4234:
4224:
4200:
4194:
4193:
4183:
4173:
4149:
4143:
4142:
4140:
4138:
4119:
4113:
4112:
4110:
4108:
4089:
4083:
4082:
4072:
4040:
4034:
4033:
3997:
3991:
3990:
3954:
3948:
3947:
3911:
3905:
3904:
3894:
3883:10.1172/JCI23994
3862:
3856:
3855:
3845:
3813:
3807:
3806:
3804:
3802:
3796:
3757:
3748:
3742:
3741:
3705:
3699:
3698:
3688:
3679:(8): 1419–1427.
3664:
3658:
3657:
3647:
3615:
3609:
3608:
3580:
3574:
3573:
3563:
3531:
3525:
3524:
3506:
3497:(7): 2059–2063.
3482:
3476:
3475:
3473:
3471:
3465:
3434:
3425:
3419:
3418:
3408:
3384:
3378:
3377:
3367:
3335:
3329:
3328:
3300:
3294:
3293:
3283:
3251:
3238:
3237:
3201:
3195:
3194:
3174:
3168:
3167:
3165:
3163:
3157:
3146:
3137:
3131:
3130:
3120:
3110:
3086:
3080:
3079:
3069:
3059:
3035:
3014:
3013:
3011:
3009:
2985:
2979:
2978:
2968:
2944:
2938:
2937:
2909:
2903:
2902:
2874:
2868:
2867:
2842:(8): 1598–1601.
2830:
2824:
2823:
2821:
2819:
2800:
2794:
2793:
2790:
2788:
2786:
2772:
2765:
2748:
2747:
2745:
2743:
2734:. 13 June 2024.
2724:
2718:
2717:
2715:
2713:
2704:. 18 July 2024.
2694:
2688:
2687:
2685:
2683:
2664:
2658:
2657:
2655:
2653:
2634:
2628:
2627:
2625:
2623:
2604:
2598:
2597:
2595:
2593:
2574:
2568:
2567:
2565:
2563:
2544:
2538:
2537:
2535:
2533:
2514:
2508:
2507:
2505:
2503:
2484:
2478:
2477:
2475:
2473:
2454:
2448:
2447:
2445:
2443:
2424:
2418:
2417:
2415:
2413:
2404:. 8 March 2023.
2394:
2388:
2387:
2385:
2383:
2374:. 1 March 2024.
2364:
2358:
2357:
2355:
2353:
2344:. 1 March 2024.
2334:
2328:
2327:
2325:
2323:
2300:
2294:
2293:
2291:
2289:
2283:
2276:
2268:
2262:
2261:
2259:
2257:
2251:
2240:
2232:
2226:
2224:
2222:
2220:
2202:"Flebogamma DIF"
2198:
2177:
2176:
2174:
2172:
2150:
2144:
2143:
2141:
2139:
2117:
2111:
2109:
2107:
2105:
2083:
2054:
2053:
2025:
2019:
2018:
2016:
2014:
1995:
1989:
1988:
1986:
1984:
1965:
1959:
1958:
1956:
1954:
1935:
1929:
1928:
1926:
1924:
1913:www.blood.gov.au
1905:
1899:
1898:
1880:
1856:
1850:
1849:
1831:
1807:
1801:
1800:
1790:
1758:
1752:
1751:
1741:
1717:
1708:
1707:
1705:
1686:
1680:
1679:
1677:
1658:
1652:
1651:
1627:
1621:
1620:
1603:
1586:
1585:
1583:
1581:
1566:
1545:
1544:
1542:
1540:
1518:
1509:
1508:
1506:
1504:
1485:
1476:
1475:
1473:
1471:
1452:
1443:
1442:
1440:
1438:
1419:
1410:
1409:
1407:
1405:
1386:
1377:
1376:
1374:
1372:
1351:
1345:
1344:
1342:
1340:
1319:
1313:
1312:
1310:
1308:
1289:
1283:
1282:
1280:
1278:
1259:
1253:
1252:
1250:
1248:
1239:. 21 June 2022.
1229:
1223:
1222:
1220:
1218:
1209:. 21 June 2022.
1199:
1193:
1192:
1190:
1188:
1179:. 15 July 2022.
1166:
1103:
1098:
1043:varicella-zoster
937:Fc glycosylation
780:hemolytic anemia
699:Brands include:
509:Kawasaki disease
378:Kawasaki disease
348:
312:
281:
278:
269:
266:
258:
255:
245:
242:
220:
169:
166:
148:
137:
134:
121:
82:
80:
76:
68:
65:
38:
37:
30:
21:
5262:
5261:
5257:
5256:
5255:
5253:
5252:
5251:
5217:
5216:
5215:
5205:
5203:
5195:
5193:
5188:
5167:
5146:
5093:Other equipment
5088:
5053:
5032:
5014:
4988:
4965:
4943:Volume expander
4937:
4919:
4914:Cryoprecipitate
4910:Cryosupernatant
4876:
4871:
4841:
4836:
4779:
4761:
4719:
4712:
4682:
4681:
4634:
4630:
4593:
4589:
4579:
4577:
4572:. 20 May 2020.
4564:
4563:
4559:
4554:on 7 June 2013.
4546:
4545:
4541:
4531:
4529:
4520:
4519:
4515:
4505:
4503:
4486:
4482:
4472:
4470:
4457:
4456:
4452:
4442:
4440:
4436:
4429:
4425:
4424:
4417:
4407:
4405:
4401:
4390:
4384:
4380:
4370:
4368:
4364:
4353:
4347:
4343:
4333:
4331:
4314:
4313:
4309:
4299:
4297:
4293:
4286:
4282:
4281:
4277:
4267:
4265:
4250:Washington Post
4242:
4238:
4201:
4197:
4150:
4146:
4136:
4134:
4129:. 20 May 2021.
4121:
4120:
4116:
4106:
4104:
4091:
4090:
4086:
4041:
4037:
3998:
3994:
3955:
3951:
3916:Nature Medicine
3912:
3908:
3863:
3859:
3814:
3810:
3800:
3798:
3794:
3755:
3749:
3745:
3706:
3702:
3665:
3661:
3616:
3612:
3581:
3577:
3532:
3528:
3483:
3479:
3469:
3467:
3463:
3443:(11): 789–792.
3432:
3426:
3422:
3399:(11): 491–498.
3385:
3381:
3336:
3332:
3301:
3297:
3252:
3241:
3202:
3198:
3175:
3171:
3161:
3159:
3155:
3144:
3138:
3134:
3087:
3083:
3036:
3017:
3007:
3005:
3004:on 5 March 2016
2986:
2982:
2945:
2941:
2910:
2906:
2875:
2871:
2831:
2827:
2817:
2815:
2802:
2801:
2797:
2791:
2784:
2782:
2767:
2766:
2751:
2741:
2739:
2726:
2725:
2721:
2711:
2709:
2696:
2695:
2691:
2681:
2679:
2666:
2665:
2661:
2651:
2649:
2636:
2635:
2631:
2621:
2619:
2606:
2605:
2601:
2591:
2589:
2576:
2575:
2571:
2561:
2559:
2546:
2545:
2541:
2531:
2529:
2516:
2515:
2511:
2501:
2499:
2486:
2485:
2481:
2471:
2469:
2456:
2455:
2451:
2441:
2439:
2426:
2425:
2421:
2411:
2409:
2396:
2395:
2391:
2381:
2379:
2366:
2365:
2361:
2351:
2349:
2336:
2335:
2331:
2321:
2319:
2302:
2301:
2297:
2287:
2285:
2281:
2274:
2270:
2269:
2265:
2255:
2253:
2249:
2238:
2234:
2233:
2229:
2218:
2216:
2200:
2199:
2180:
2170:
2168:
2152:
2151:
2147:
2137:
2135:
2121:"Privigen EPAR"
2119:
2118:
2114:
2103:
2101:
2087:"Hizentra EPAR"
2085:
2084:
2057:
2026:
2022:
2012:
2010:
2005:. 12 May 2021.
1997:
1996:
1992:
1982:
1980:
1967:
1966:
1962:
1952:
1950:
1937:
1936:
1932:
1922:
1920:
1907:
1906:
1902:
1857:
1853:
1808:
1804:
1773:(S1): S74–S78.
1759:
1755:
1718:
1711:
1687:
1683:
1659:
1655:
1644:
1628:
1624:
1617:
1605:
1604:
1589:
1579:
1577:
1568:
1567:
1548:
1538:
1536:
1520:
1519:
1512:
1502:
1500:
1487:
1486:
1479:
1469:
1467:
1454:
1453:
1446:
1436:
1434:
1421:
1420:
1413:
1403:
1401:
1388:
1387:
1380:
1370:
1368:
1353:
1352:
1348:
1338:
1336:
1321:
1320:
1316:
1306:
1304:
1291:
1290:
1286:
1276:
1274:
1261:
1260:
1256:
1246:
1244:
1231:
1230:
1226:
1216:
1214:
1201:
1200:
1196:
1186:
1184:
1170:"Xembify APMDS"
1168:
1167:
1160:
1155:
1135:
1122:
1110:
1101:
1096:
1088:
1083:
1011:immunoglobulins
1007:
957:dendritic cells
922:
877:
868:
847:
842:
746:diphenhydramine
737:
677:
657:
571:
562:
547:
493:dermatomyositis
480:
413:kidney problems
351:
331:
315:
290:
224:
184:
177:
158:
151:
146:Immune globulin
69:
63:
60:
39:
35:
28:
23:
22:
15:
12:
11:
5:
5260:
5250:
5249:
5244:
5239:
5234:
5229:
5214:
5213:
5190:
5189:
5187:
5186:
5181:
5175:
5173:
5169:
5168:
5166:
5165:
5160:
5154:
5152:
5151:Specific risks
5148:
5147:
5145:
5144:
5143:
5142:
5137:
5132:
5127:
5122:
5117:
5112:
5102:
5096:
5094:
5090:
5089:
5087:
5086:
5081:
5071:
5065:
5063:
5059:
5058:
5055:
5054:
5052:
5051:
5046:
5044:Drug injection
5040:
5038:
5034:
5033:
5031:
5030:
5024:
5022:
5016:
5015:
5013:
5012:
5007:
5005:Gamma globulin
5002:
4996:
4994:
4990:
4989:
4987:
4986:
4981:
4975:
4973:
4967:
4966:
4964:
4963:
4961:Sugar solution
4958:
4953:
4947:
4945:
4939:
4938:
4936:
4935:
4929:
4927:
4921:
4920:
4918:
4917:
4899:
4893:
4891:
4882:
4878:
4877:
4870:
4869:
4862:
4855:
4847:
4838:
4837:
4835:
4834:
4829:
4824:
4819:
4814:
4809:
4804:
4799:
4793:
4791:
4785:
4784:
4781:
4780:
4778:
4777:
4771:
4769:
4763:
4762:
4760:
4759:
4754:
4749:
4744:
4738:
4736:
4727:
4721:
4720:
4711:
4710:
4703:
4696:
4688:
4680:
4679:
4628:
4587:
4557:
4539:
4513:
4496:New York Times
4480:
4450:
4415:
4378:
4341:
4307:
4275:
4236:
4222:10.1086/514294
4195:
4144:
4114:
4084:
4035:
4008:(3): 270–274.
3992:
3949:
3928:10.1038/nm1416
3922:(6): 688–692.
3906:
3857:
3828:(4): 426–429.
3808:
3743:
3700:
3659:
3610:
3591:(2): 758–765.
3575:
3526:
3477:
3420:
3379:
3330:
3295:
3239:
3196:
3169:
3132:
3081:
3015:
2980:
2939:
2904:
2885:(1): 120–123.
2869:
2825:
2810:. 9 May 2024.
2795:
2749:
2719:
2689:
2659:
2629:
2599:
2569:
2539:
2509:
2479:
2449:
2419:
2389:
2359:
2329:
2295:
2263:
2227:
2178:
2145:
2112:
2055:
2020:
1990:
1960:
1930:
1900:
1851:
1822:(6): 736–740.
1802:
1753:
1709:
1681:
1653:
1642:
1622:
1615:
1587:
1546:
1510:
1477:
1444:
1411:
1378:
1346:
1331:. 9 May 2018.
1314:
1284:
1254:
1224:
1194:
1157:
1156:
1154:
1151:
1139:clinical trial
1134:
1131:
1121:
1118:
1109:
1106:
1087:
1084:
1082:
1079:
1006:
1003:
999:interleukin-10
953:immune complex
921:
918:
876:
873:
867:
864:
846:
843:
841:
838:
802:, hypokalemic
736:
733:
732:
731:
728:
725:
722:
719:
716:
713:
710:
707:
704:
685:immunoglobulin
676:
673:
656:
655:United Kingdom
653:
652:
651:
648:
645:
638:
637:
634:
630:
626:
622:
615:
614:
611:
608:
605:
602:
595:
594:
591:
587:
583:
570:
569:European Union
567:
561:
558:
546:
543:
479:
476:
429:IgA deficiency
402:under the skin
353:
352:
350:
349:
341:
339:
333:
332:
330:
329:
325:
323:
317:
316:
314:
313:
305:
303:
297:
296:
292:
291:
289:
288:
285:
276:
264:
253:
239:
237:
231:
230:
226:
225:
223:
222:
209:
207:
201:
200:
187:
185:administration
179:
178:
176:
175:
173:
163:
161:
153:
152:
150:
149:
131:
129:
123:
122:
115:
105:
104:
101:
97:
96:
93:
87:
86:
71:
70:
42:
40:
33:
26:
9:
6:
4:
3:
2:
5259:
5248:
5245:
5243:
5240:
5238:
5235:
5233:
5230:
5228:
5227:Glycoproteins
5225:
5224:
5222:
5212:
5202:
5201:
5198:
5185:
5182:
5180:
5177:
5176:
5174:
5170:
5164:
5163:Extravasation
5161:
5159:
5156:
5155:
5153:
5149:
5141:
5138:
5136:
5133:
5131:
5128:
5126:
5123:
5121:
5118:
5116:
5113:
5111:
5108:
5107:
5106:
5103:
5101:
5100:Infusion pump
5098:
5097:
5095:
5091:
5085:
5082:
5079:
5075:
5072:
5070:
5067:
5066:
5064:
5062:Access points
5060:
5050:
5049:Ascorbic acid
5047:
5045:
5042:
5041:
5039:
5035:
5029:
5026:
5025:
5023:
5021:
5017:
5011:
5008:
5006:
5003:
5001:
4998:
4997:
4995:
4991:
4985:
4982:
4980:
4977:
4976:
4974:
4972:
4968:
4962:
4959:
4957:
4956:Normal saline
4954:
4952:
4949:
4948:
4946:
4944:
4940:
4934:
4931:
4930:
4928:
4926:
4922:
4915:
4911:
4907:
4903:
4900:
4898:
4895:
4894:
4892:
4890:
4886:
4883:
4879:
4875:
4868:
4863:
4861:
4856:
4854:
4849:
4848:
4845:
4833:
4830:
4828:
4825:
4823:
4820:
4818:
4817:Obiltoxaximab
4815:
4813:
4810:
4808:
4805:
4803:
4800:
4798:
4795:
4794:
4792:
4790:
4786:
4776:
4773:
4772:
4770:
4768:
4764:
4758:
4755:
4753:
4750:
4748:
4745:
4743:
4740:
4739:
4737:
4735:
4731:
4728:
4726:
4722:
4717:
4709:
4704:
4702:
4697:
4695:
4690:
4689:
4686:
4675:
4671:
4667:
4663:
4659:
4655:
4651:
4647:
4643:
4639:
4632:
4624:
4620:
4615:
4610:
4606:
4602:
4598:
4591:
4575:
4571:
4567:
4561:
4553:
4549:
4543:
4527:
4523:
4517:
4501:
4497:
4492:
4484:
4468:
4464:
4460:
4454:
4435:
4428:
4422:
4420:
4400:
4396:
4389:
4382:
4363:
4359:
4352:
4345:
4329:
4325:
4323:
4317:
4311:
4292:
4285:
4279:
4263:
4259:
4255:
4251:
4247:
4240:
4232:
4228:
4223:
4218:
4214:
4210:
4206:
4199:
4191:
4187:
4182:
4177:
4172:
4167:
4163:
4159:
4155:
4148:
4132:
4128:
4124:
4118:
4102:
4098:
4094:
4088:
4080:
4076:
4071:
4066:
4062:
4058:
4054:
4050:
4046:
4039:
4031:
4027:
4023:
4019:
4015:
4011:
4007:
4003:
3996:
3988:
3984:
3980:
3976:
3972:
3968:
3964:
3960:
3953:
3945:
3941:
3937:
3933:
3929:
3925:
3921:
3917:
3910:
3902:
3898:
3893:
3888:
3884:
3880:
3876:
3872:
3868:
3861:
3853:
3849:
3844:
3839:
3835:
3831:
3827:
3823:
3819:
3812:
3793:
3789:
3785:
3781:
3777:
3773:
3769:
3765:
3761:
3754:
3747:
3739:
3735:
3731:
3727:
3723:
3719:
3715:
3711:
3704:
3696:
3692:
3687:
3682:
3678:
3674:
3670:
3663:
3655:
3651:
3646:
3641:
3637:
3633:
3629:
3625:
3621:
3614:
3606:
3602:
3598:
3594:
3590:
3586:
3579:
3571:
3567:
3562:
3557:
3553:
3549:
3545:
3541:
3537:
3530:
3522:
3518:
3514:
3510:
3505:
3500:
3496:
3492:
3488:
3481:
3462:
3458:
3454:
3450:
3446:
3442:
3438:
3431:
3424:
3416:
3412:
3407:
3402:
3398:
3394:
3390:
3383:
3375:
3371:
3366:
3361:
3357:
3353:
3349:
3345:
3341:
3334:
3326:
3322:
3318:
3315:(2): 467–68.
3314:
3310:
3306:
3299:
3291:
3287:
3282:
3277:
3273:
3269:
3265:
3261:
3257:
3250:
3248:
3246:
3244:
3235:
3231:
3227:
3223:
3219:
3215:
3211:
3207:
3200:
3192:
3188:
3185:(3): 289–93.
3184:
3180:
3173:
3154:
3150:
3143:
3136:
3128:
3124:
3119:
3114:
3109:
3104:
3100:
3096:
3092:
3085:
3077:
3073:
3068:
3063:
3058:
3053:
3049:
3045:
3041:
3034:
3032:
3030:
3028:
3026:
3024:
3022:
3020:
3003:
2999:
2995:
2991:
2984:
2976:
2972:
2967:
2962:
2958:
2954:
2950:
2943:
2935:
2931:
2927:
2923:
2919:
2915:
2908:
2900:
2896:
2892:
2888:
2884:
2880:
2873:
2865:
2861:
2857:
2853:
2849:
2845:
2841:
2837:
2829:
2813:
2809:
2808:www.pcori.org
2805:
2799:
2780:
2776:
2771:
2764:
2762:
2760:
2758:
2756:
2754:
2737:
2733:
2729:
2723:
2707:
2703:
2699:
2693:
2677:
2673:
2669:
2663:
2647:
2643:
2639:
2633:
2617:
2613:
2609:
2603:
2587:
2583:
2579:
2573:
2557:
2553:
2549:
2543:
2527:
2523:
2519:
2513:
2497:
2493:
2489:
2483:
2467:
2463:
2459:
2453:
2437:
2433:
2429:
2423:
2407:
2403:
2399:
2393:
2377:
2373:
2369:
2363:
2347:
2343:
2339:
2333:
2317:
2313:
2311:
2305:
2299:
2280:
2273:
2267:
2248:
2244:
2237:
2231:
2214:
2210:
2208:
2203:
2197:
2195:
2193:
2191:
2189:
2187:
2185:
2183:
2166:
2162:
2160:
2155:
2154:"Kiovig EPAR"
2149:
2133:
2129:
2127:
2122:
2116:
2099:
2095:
2093:
2088:
2082:
2080:
2078:
2076:
2074:
2072:
2070:
2068:
2066:
2064:
2062:
2060:
2051:
2047:
2043:
2039:
2035:
2031:
2024:
2008:
2004:
2000:
1994:
1978:
1974:
1970:
1964:
1948:
1944:
1940:
1934:
1918:
1914:
1910:
1904:
1896:
1892:
1888:
1884:
1879:
1874:
1870:
1866:
1862:
1855:
1847:
1843:
1839:
1835:
1830:
1825:
1821:
1817:
1813:
1806:
1798:
1794:
1789:
1784:
1780:
1776:
1772:
1768:
1764:
1757:
1749:
1745:
1740:
1735:
1731:
1727:
1723:
1716:
1714:
1704:
1699:
1695:
1691:
1685:
1676:
1671:
1667:
1663:
1657:
1649:
1645:
1643:9780124115545
1639:
1635:
1634:
1626:
1618:
1616:9780857111562
1612:
1608:
1602:
1600:
1598:
1596:
1594:
1592:
1575:
1571:
1565:
1563:
1561:
1559:
1557:
1555:
1553:
1551:
1534:
1530:
1528:
1523:
1522:"HyQvia EPAR"
1517:
1515:
1498:
1494:
1490:
1484:
1482:
1465:
1461:
1457:
1451:
1449:
1432:
1428:
1424:
1418:
1416:
1399:
1395:
1391:
1385:
1383:
1366:
1362:
1361:
1360:Health Canada
1356:
1350:
1334:
1330:
1329:
1328:Health Canada
1324:
1318:
1302:
1298:
1297:Health Canada
1294:
1288:
1272:
1268:
1267:Health Canada
1264:
1258:
1242:
1238:
1234:
1228:
1212:
1208:
1204:
1198:
1182:
1178:
1176:
1171:
1165:
1163:
1158:
1150:
1148:
1144:
1140:
1130:
1126:
1120:Supply issues
1117:
1115:
1105:
1099:
1093:
1078:
1076:
1071:
1067:
1062:
1060:
1056:
1053:that provide
1052:
1048:
1044:
1040:
1036:
1032:
1028:
1024:
1020:
1016:
1012:
1002:
1000:
996:
992:
987:
985:
981:
977:
973:
969:
965:
960:
958:
954:
948:
946:
942:
938:
933:
931:
927:
917:
915:
910:
908:
904:
898:
895:
891:
885:
882:
872:
863:
860:
856:
852:
837:
835:
830:
828:
824:
820:
815:
813:
809:
805:
801:
797:
793:
789:
785:
781:
777:
773:
769:
765:
760:
758:
753:
751:
747:
743:
742:acetaminophen
729:
726:
723:
720:
717:
714:
711:
708:
705:
702:
701:
700:
697:
695:
691:
686:
682:
675:United States
672:
670:
666:
662:
649:
646:
643:
642:
641:
635:
631:
629:immunisation;
627:
623:
620:
619:
618:
612:
609:
606:
603:
600:
599:
598:
592:
588:
584:
581:
580:
579:
575:
566:
557:
554:
551:
542:
540:
536:
533:
528:
526:
522:
518:
514:
510:
506:
502:
498:
494:
490:
486:
475:
473:
469:
465:
461:
457:
453:
449:
444:
442:
438:
434:
430:
426:
422:
418:
414:
410:
405:
403:
399:
395:
391:
387:
383:
379:
375:
371:
367:
363:
359:
347:
343:
342:
340:
338:
334:
327:
326:
324:
322:
318:
311:
307:
306:
304:
302:
298:
293:
286:
284: Rx-only
277:
275:
265:
263:
254:
251:
241:
240:
238:
236:
232:
227:
219:
214:
211:
210:
208:
206:
202:
199:
195:
194:intramuscular
191:
188:
186:
180:
174:
165:
164:
162:
160:
154:
147:
142:
133:
132:
130:
128:
124:
120:
116:
114:
110:
106:
102:
98:
94:
92:
88:
85:Clinical data
83:
75:
67:
64:December 2020
58:
54:
53:
48:
47:
41:
32:
31:
19:
5158:Air embolism
4999:
4797:Bezlotoxumab
4641:
4637:
4631:
4604:
4600:
4590:
4578:. Retrieved
4569:
4560:
4552:the original
4542:
4530:. Retrieved
4516:
4504:. Retrieved
4495:
4483:
4471:. Retrieved
4462:
4453:
4441:. Retrieved
4406:. Retrieved
4394:
4381:
4369:. Retrieved
4344:
4332:. Retrieved
4319:
4310:
4298:. Retrieved
4278:
4266:. Retrieved
4249:
4239:
4212:
4208:
4198:
4161:
4157:
4147:
4135:. Retrieved
4127:Plasvacc USA
4126:
4117:
4105:. Retrieved
4096:
4093:"Antivenoms"
4087:
4055:(1): 80–90.
4052:
4048:
4038:
4005:
4001:
3995:
3962:
3958:
3952:
3919:
3915:
3909:
3877:(1): 25–27.
3874:
3870:
3860:
3825:
3821:
3811:
3799:. Retrieved
3763:
3759:
3746:
3713:
3709:
3703:
3676:
3672:
3662:
3627:
3623:
3613:
3588:
3584:
3578:
3543:
3539:
3529:
3494:
3490:
3480:
3468:. Retrieved
3440:
3436:
3423:
3396:
3392:
3382:
3350:(1): 11–15.
3347:
3343:
3333:
3312:
3308:
3298:
3263:
3259:
3209:
3205:
3199:
3182:
3178:
3172:
3160:. Retrieved
3148:
3135:
3098:
3094:
3084:
3047:
3043:
3006:. Retrieved
3002:the original
2997:
2993:
2983:
2956:
2952:
2942:
2917:
2913:
2907:
2882:
2878:
2872:
2839:
2835:
2828:
2816:. Retrieved
2807:
2798:
2783:. Retrieved
2774:
2740:. Retrieved
2731:
2722:
2710:. Retrieved
2701:
2692:
2680:. Retrieved
2671:
2662:
2650:. Retrieved
2641:
2632:
2620:. Retrieved
2611:
2602:
2590:. Retrieved
2581:
2572:
2560:. Retrieved
2551:
2542:
2530:. Retrieved
2521:
2512:
2500:. Retrieved
2491:
2482:
2470:. Retrieved
2461:
2452:
2440:. Retrieved
2431:
2422:
2410:. Retrieved
2401:
2392:
2380:. Retrieved
2371:
2362:
2350:. Retrieved
2341:
2332:
2320:. Retrieved
2307:
2298:
2286:. Retrieved
2266:
2254:. Retrieved
2242:
2230:
2217:. Retrieved
2205:
2169:. Retrieved
2157:
2148:
2136:. Retrieved
2124:
2115:
2102:. Retrieved
2090:
2033:
2029:
2023:
2011:. Retrieved
2002:
1993:
1981:. Retrieved
1972:
1963:
1951:. Retrieved
1942:
1933:
1921:. Retrieved
1912:
1903:
1868:
1864:
1854:
1819:
1815:
1805:
1770:
1766:
1756:
1729:
1725:
1703:10665/345533
1693:
1684:
1675:10665/325771
1665:
1656:
1632:
1625:
1606:
1578:. Retrieved
1537:. Retrieved
1525:
1501:. Retrieved
1492:
1468:. Retrieved
1459:
1435:. Retrieved
1426:
1402:. Retrieved
1393:
1369:. Retrieved
1358:
1349:
1337:. Retrieved
1326:
1317:
1305:. Retrieved
1296:
1287:
1275:. Retrieved
1266:
1257:
1245:. Retrieved
1236:
1227:
1215:. Retrieved
1206:
1197:
1185:. Retrieved
1173:
1136:
1127:
1123:
1111:
1089:
1064:Hyperimmune
1063:
1059:side effects
1014:
1008:
988:
972:phagocytosis
961:
949:
934:
926:inflammation
923:
911:
899:
893:
889:
886:
881:subcutaneous
878:
869:
848:
831:
816:
794:, backache,
772:hyponatremia
761:
754:
738:
735:Side effects
698:
678:
658:
639:
616:
596:
576:
572:
563:
555:
552:
548:
529:
481:
478:Medical uses
445:
437:blood plasma
406:
357:
356:
235:Legal status
229:Legal status
198:subcutaneous
172: Exempt
127:License data
74:
61:
50:
44:
4993:Medications
4897:Whole blood
4827:Raxibacumab
4822:Palivizumab
4802:Motavizumab
4473:14 November
4408:23 November
4300:23 November
4097:www.who.int
3266:(6): 1–13.
3162:24 November
3008:23 November
2920:(1): 7–10.
2836:Transfusion
2785:23 November
2562:26 February
2398:"Gamunex-C"
2322:22 December
2013:6 September
1983:14 November
1953:14 November
1923:14 November
1114:biologicals
1108:Brand names
1075:Ebola virus
1031:hepatitis B
968:macrophages
945:Fc receptor
855:intravenous
819:neutropenia
804:nephropathy
792:anaphylaxis
768:tachycardia
586:infections;
456:hepatitis B
421:blood clots
417:anaphylaxis
295:Identifiers
190:Intravenous
100:Other names
91:Trade names
5221:Categories
5010:Interferon
4812:Nirsevimab
4443:7 December
4386:Berman K.
4316:"Hizentra"
4164:(9): 606.
3470:12 January
3309:Pediatrics
3140:Powell L.
2458:"Hizentra"
2288:5 December
2256:5 December
1999:"Cutaquig"
1728:(Review).
1153:References
1100:11.20 and
903:Vivaglobin
784:thrombosis
750:prednisone
362:antibodies
346:66Y330CJHS
321:ChemSpider
301:CAS Number
4807:Nebacumab
4775:Antivenom
4767:Antiserum
4395:IG Living
4258:0190-8286
3630:(1): 50.
2728:"Yimmugo"
2698:"Xembify"
2638:"Panzyga"
2578:"Octagam"
2368:"Bivigam"
2338:"Asceniv"
1895:221433035
1816:Neurology
1580:8 January
1086:Economics
1025:in their
991:microglia
984:monocytes
827:apoptosis
788:hepatitis
776:hemolysis
545:Australia
532:pediatric
433:pregnancy
310:9007-83-4
183:Routes of
157:Pregnancy
119:Monograph
113:Drugs.com
5211:Medicine
5172:See also
4674:13665273
4666:29746978
4644:: 1–10.
4623:19439743
4574:Archived
4526:Archived
4500:Archived
4467:Archived
4434:Archived
4399:Archived
4371:20 March
4362:Archived
4328:Archived
4291:Archived
4262:Archived
4190:36136544
4131:Archived
4101:Archived
4079:25030060
4030:18239570
4022:16687052
3979:14598046
3944:40468774
3936:16715090
3901:15630438
3852:31797906
3792:Archived
3788:54476352
3780:30529242
3730:21281961
3695:23847198
3654:31974400
3605:12393386
3570:24760152
3521:29700587
3513:24700174
3461:Archived
3457:28916232
3415:28666326
3374:17227911
3325:Archived
3290:25578468
3153:Archived
3127:19883424
3076:20169031
3050:: 1–10.
2975:33373142
2934:15654271
2856:18466176
2812:Archived
2779:Archived
2742:5 August
2736:Archived
2712:5 August
2706:Archived
2676:Archived
2672:DailyMed
2652:5 August
2646:Archived
2616:Archived
2612:DailyMed
2592:5 August
2586:Archived
2556:Archived
2552:DailyMed
2532:5 August
2526:Archived
2518:"Hyqvia"
2496:Archived
2492:DailyMed
2472:5 August
2466:Archived
2436:Archived
2432:DailyMed
2412:5 August
2406:Archived
2382:5 August
2376:Archived
2352:5 August
2346:Archived
2316:Archived
2304:"Alyglo"
2279:Archived
2247:Archived
2213:Archived
2165:Archived
2132:Archived
2098:Archived
2050:17397769
2007:Archived
1977:Archived
1947:Archived
1917:Archived
1887:25231064
1846:20577426
1838:14504313
1797:20396937
1748:16580469
1692:(2021).
1664:(2019).
1648:Archived
1574:Archived
1533:Archived
1497:Archived
1493:DailyMed
1464:Archived
1460:DailyMed
1431:Archived
1427:DailyMed
1398:Archived
1394:DailyMed
1371:17 April
1365:Archived
1339:13 April
1333:Archived
1307:6 August
1301:Archived
1271:Archived
1247:10 April
1241:Archived
1217:10 April
1211:Archived
1181:Archived
1147:COVID-19
1133:Research
1094:between
1051:vaccines
1019:antibody
669:HIV/AIDS
633:marrow);
499:such as
382:HIV/AIDS
205:ATC code
159:category
141:DailyMed
4971:Buffers
4646:Bibcode
4638:Toxicon
4532:19 July
4506:19 July
4360:(FDA).
4231:9988187
4181:9503307
4070:4264590
3987:5945755
3843:7109030
3738:2323773
3645:6978335
3561:4025610
3365:2118416
3281:4340844
3234:9774279
3214:Bibcode
3206:Science
3118:2801034
3067:2817783
2899:8447553
2864:6010463
2818:11 July
2775:Dynamed
2219:15 July
2171:14 July
2138:14 July
1788:2883091
1539:14 July
1503:3 March
1187:17 July
1041:toxin,
1039:tetanus
1023:antigen
980:B cells
976:T cells
625:failed;
590:donor);
464:tetanus
441:viruses
386:measles
260::
221:)
215: (
143::
57:discuss
5197:Portal
4672:
4664:
4621:
4580:28 May
4268:23 May
4256:
4229:
4188:
4178:
4158:Toxins
4137:23 May
4107:23 May
4077:
4067:
4028:
4020:
3985:
3977:
3942:
3934:
3899:
3892:539209
3889:
3850:
3840:
3801:8 July
3786:
3778:
3736:
3728:
3693:
3652:
3642:
3603:
3568:
3558:
3519:
3511:
3455:
3413:
3372:
3362:
3288:
3278:
3232:
3125:
3115:
3074:
3064:
2973:
2932:
2897:
2862:
2854:
2682:9 June
2622:9 June
2502:9 June
2442:9 June
2048:
1893:
1885:
1844:
1836:
1795:
1785:
1746:
1640:
1613:
1470:9 June
1437:9 June
1404:9 June
1277:7 June
1070:plasma
1035:rabies
1027:plasma
982:, and
894:ad hoc
890:ad hoc
810:, and
694:PANDAS
665:sepsis
560:Canada
470:, and
460:rabies
423:, and
274:℞-only
272:
262:℞-only
248:
139:
5037:Other
5028:Sugar
4670:S2CID
4437:(PDF)
4430:(PDF)
4402:(PDF)
4391:(PDF)
4365:(PDF)
4354:(PDF)
4334:3 May
4324:(FDA)
4320:U.S.
4294:(PDF)
4287:(PDF)
4026:S2CID
3983:S2CID
3940:S2CID
3795:(PDF)
3784:S2CID
3756:(PDF)
3734:S2CID
3673:Blood
3585:Blood
3517:S2CID
3464:(PDF)
3433:(PDF)
3156:(PDF)
3145:(PDF)
2860:S2CID
2312:(FDA)
2308:U.S.
2282:(PDF)
2275:(PDF)
2250:(PDF)
2239:(PDF)
2209:(EMA)
2161:(EMA)
2128:(EMA)
2104:2 May
2094:(EMA)
1891:S2CID
1842:S2CID
1529:(EMA)
1177:(TGA)
1066:serum
859:polio
400:, or
213:J06BA
46:split
5130:Port
5120:PICC
4902:PF24
4734:IVIG
4662:PMID
4619:PMID
4582:2020
4534:2012
4508:2012
4475:2019
4445:2015
4410:2015
4373:2018
4336:2020
4302:2015
4270:2023
4254:ISSN
4227:PMID
4186:PMID
4139:2023
4109:2023
4075:PMID
4018:PMID
3975:PMID
3932:PMID
3897:PMID
3848:PMID
3803:2022
3776:PMID
3726:PMID
3691:PMID
3650:PMID
3601:PMID
3566:PMID
3509:PMID
3472:2022
3453:PMID
3411:PMID
3370:PMID
3286:PMID
3230:PMID
3164:2015
3123:PMID
3072:PMID
3010:2015
2971:PMID
2930:PMID
2895:PMID
2852:PMID
2820:2024
2787:2015
2744:2024
2714:2024
2684:2021
2654:2024
2624:2021
2594:2024
2564:2024
2534:2024
2504:2021
2474:2024
2444:2021
2414:2024
2384:2024
2354:2024
2324:2023
2290:2015
2258:2015
2221:2020
2173:2020
2140:2020
2106:2020
2046:PMID
2015:2021
1985:2019
1955:2019
1925:2019
1883:PMID
1834:PMID
1793:PMID
1744:PMID
1638:ISBN
1611:ISBN
1582:2017
1541:2020
1505:2024
1472:2021
1439:2021
1406:2021
1373:2024
1341:2024
1309:2022
1279:2022
1249:2023
1219:2023
1189:2022
1068:and
997:and
744:and
679:The
523:and
507:and
398:vein
396:, a
384:and
337:UNII
328:none
109:AHFS
18:IVIG
5115:MLC
5110:SLC
5105:CVC
4716:J06
4654:doi
4642:150
4609:doi
4605:360
4217:doi
4213:179
4176:PMC
4166:doi
4065:PMC
4057:doi
4053:211
4010:doi
3967:doi
3924:doi
3887:PMC
3879:doi
3875:115
3838:PMC
3830:doi
3768:doi
3764:144
3718:doi
3714:127
3681:doi
3677:122
3640:PMC
3632:doi
3593:doi
3589:101
3556:PMC
3548:doi
3544:192
3499:doi
3445:doi
3401:doi
3360:PMC
3352:doi
3348:204
3317:doi
3313:110
3276:PMC
3268:doi
3222:doi
3210:282
3187:doi
3113:PMC
3103:doi
3099:158
3062:PMC
3052:doi
2961:doi
2922:doi
2887:doi
2844:doi
2038:doi
1873:doi
1824:doi
1783:PMC
1775:doi
1734:doi
1730:117
1698:hdl
1670:hdl
1112:As
1092:NHS
930:Fas
535:HIV
489:IgG
218:WHO
59:)
55:. (
5223::
4912:+
4668:.
4660:.
4652:.
4640:.
4617:.
4603:.
4599:.
4568:.
4498:.
4494:.
4465:.
4461:.
4418:^
4393:.
4318:.
4260:.
4252:.
4248:.
4225:.
4211:.
4207:.
4184:.
4174:.
4162:14
4160:.
4156:.
4125:.
4099:.
4095:.
4073:.
4063:.
4051:.
4047:.
4024:.
4016:.
4006:28
4004:.
3981:.
3973:.
3963:24
3961:.
3938:.
3930:.
3920:12
3918:.
3895:.
3885:.
3873:.
3869:.
3846:.
3836:.
3826:17
3824:.
3820:.
3790:.
3782:.
3774:.
3762:.
3758:.
3732:.
3724:.
3712:.
3689:.
3675:.
3671:.
3648:.
3638:.
3628:11
3626:.
3622:.
3599:.
3587:.
3564:.
3554:.
3542:.
3538:.
3515:.
3507:.
3495:44
3493:.
3489:.
3459:.
3451:.
3441:38
3439:.
3435:.
3409:.
3397:29
3395:.
3391:.
3368:.
3358:.
3346:.
3342:.
3323:.
3311:.
3307:.
3284:.
3274:.
3264:57
3262:.
3258:.
3242:^
3228:.
3220:.
3208:.
3181:.
3151:.
3147:.
3121:.
3111:.
3097:.
3093:.
3070:.
3060:.
3046:.
3042:.
3018:^
2996:.
2992:.
2969:.
2957:18
2955:.
2951:.
2928:.
2918:27
2916:.
2893:.
2883:15
2881:.
2858:.
2850:.
2840:48
2838:.
2806:.
2777:.
2773:.
2752:^
2730:.
2700:.
2674:.
2670:.
2640:.
2614:.
2610:.
2580:.
2550:.
2520:.
2494:.
2490:.
2460:.
2434:.
2430:.
2400:.
2370:.
2340:.
2306:.
2245:.
2241:.
2211:.
2204:.
2181:^
2163:.
2156:.
2130:.
2123:.
2096:.
2089:.
2058:^
2044:.
2034:21
2032:.
2001:.
1975:.
1971:.
1945:.
1941:.
1915:.
1911:.
1889:.
1881:.
1869:14
1867:.
1840:.
1832:.
1820:61
1818:.
1814:.
1791:.
1781:.
1771:30
1769:.
1765:.
1742:.
1724:.
1712:^
1646:.
1590:^
1549:^
1531:.
1524:.
1513:^
1491:.
1480:^
1462:.
1458:.
1447:^
1429:.
1425:.
1414:^
1396:.
1392:.
1381:^
1357:.
1325:.
1295:.
1265:.
1235:.
1205:.
1172:.
1161:^
1077:.
1037:,
1033:,
978:,
806:,
798:,
790:,
786:,
782:,
778:,
774:,
770:,
766:,
692:,
671:.
519:,
515:,
474:.
466:,
462:,
458:,
443:.
419:,
415:,
388:,
376:,
372:,
368:,
280:EU
268:US
257:CA
250:S4
244:AU
196:,
192:,
168:AU
136:US
5199::
5080:)
5076:(
4916:)
4908:(
4904:/
4866:e
4859:t
4852:v
4718:)
4707:e
4700:t
4693:v
4676:.
4656::
4648::
4625:.
4611::
4584:.
4536:.
4510:.
4477:.
4447:.
4412:.
4375:.
4338:.
4304:.
4272:.
4233:.
4219::
4192:.
4168::
4141:.
4111:.
4081:.
4059::
4032:.
4012::
3989:.
3969::
3946:.
3926::
3903:.
3881::
3854:.
3832::
3805:.
3770::
3740:.
3720::
3697:.
3683::
3656:.
3634::
3607:.
3595::
3572:.
3550::
3523:.
3501::
3474:.
3447::
3417:.
3403::
3376:.
3354::
3319::
3292:.
3270::
3236:.
3224::
3216::
3193:.
3189::
3183:1
3166:.
3129:.
3105::
3078:.
3054::
3048:6
3012:.
2998:3
2977:.
2963::
2936:.
2924::
2901:.
2889::
2866:.
2846::
2822:.
2789:.
2746:.
2716:.
2686:.
2656:.
2626:.
2596:.
2566:.
2536:.
2506:.
2476:.
2446:.
2416:.
2386:.
2356:.
2326:.
2292:.
2260:.
2223:.
2175:.
2142:.
2108:.
2052:.
2040::
2017:.
1987:.
1957:.
1927:.
1897:.
1875::
1848:.
1826::
1799:.
1777::
1750:.
1736::
1700::
1672::
1619:.
1584:.
1543:.
1507:.
1474:.
1441:.
1408:.
1375:.
1343:.
1311:.
1281:.
1251:.
1221:.
1191:.
1102:£
1097:£
901:(
282::
270::
246::
170::
111:/
66:)
62:(
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.